Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice

Pereira-Gillion, Céline; Marot, Mathilde; Griffoul-Espitalier, Isabelle; Andras, Lucia; Goupille, Philippe; Salliot, Carine

doi:10.3899/jrheum.170587

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SpA patient recruitment was previously described (11). Briefly, all rheumatologists who collaborated with 3 public hospitals in the Centre-Val de Loire area were asked to participate in the study via a mailed information letter.…”

Section: Study Population and Follow-upmentioning

confidence: 99%

Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study

Krajewski

Andras²,

Pereira-Gillion

et al. 2019

Joint Bone Spine

Self Cite

View full text Add to dashboard Cite

Section: Study Population and Follow-upmentioning

confidence: 99%

Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study

Krajewski

Andras²,

Pereira-Gillion

et al. 2019

Joint Bone Spine

Self Cite

View full text Add to dashboard Cite

“…Also recommended is the use of validated instruments, such as the Exercise Adherence Rating Scale (EARS), to measure the effectiveness of these interventions [85 & ,86]. Studies of adherence to recommendations for pharmacotherapy of axSpA are few and most have focused on TNFi use, reporting varied overall rates of adherence [87][88][89][90]. Measuring adherence to pharmacologic treatment recommendations for axSpA in clinical practice is not straightforward.…”

Section: Guideline Implementation In Axial Spondyloarthritismentioning

confidence: 99%

“…Studies of adherence to recommendations for pharmacotherapy of axSpA are few and most have focused on TNFi use, reporting varied overall rates of adherence [87–90]. Measuring adherence to pharmacologic treatment recommendations for axSpA in clinical practice is not straightforward.…”

Section: Guideline Implementation In Axial Spondyloarthritismentioning

confidence: 99%

Axial spondyloarthritis guidelines – aiming for maximum impact

Choufani,

Kay,

Ermann

2024

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review This review discusses international clinical practice guidelines (CPGs) for axial spondyloarthritis (axSpA) focusing on methodology, guideline quality, and implementation. Recent findings The Assessment of SpondyloArthritis International Society/European Alliance of Associations for Rheumatology (ASAS/EULAR) and Pan-American League of Associations for Rheumatology (PANLAR) recently published axSpA CPGs and updates of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) and Asia-Pacific League of Associations for Rheumatology (APLAR) CPGs are expected. GRADE has emerged as the dominant framework for CPG development and has been used by three of the four international axSpA guidelines. Notable differences exist among these guidelines in the way that the recommendations are presented. Two of the four acknowledge the need for implementation strategies, but little detail about this is provided. The few studies that have evaluated the implementation of axSpA CPGs have identified poor adherence to recommendations on physical therapy/exercise and disease activity monitoring. Implementation science has identified many barriers and facilitators affecting guideline uptake, including those related to healthcare professionals and to the guidelines themselves. Creation of a tailored implementation plan simultaneously with the CPG is recommended. Summary While methodological rigor in the creation of evidence-based recommendations is the focus of CPG development, recommendations must be presented in a user-friendly format that makes them easy to apply. ‘Living guidelines’ could facilitate keeping content up to date. Implementation is critical for the success of a CPG and should be emphasized in future axSpA guideline updates. Further research is needed to better understand the factors impacting the successful implementation of axSpA CPGs.

show abstract

Maintien thérapeutique d’un second anti-TNF alpha dans les spondyloarthrites : étude multicentrique en situation réelle

Krajewski¹,

Andras²,

Pereira-Gillion³

et al. 2020

Revue du Rhumatisme

View full text Add to dashboard Cite

Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice

Abstract: Despite high levels of knowledge of, and adherence to, recommendations for using TNF inhibitors for SpA, rheumatologists' application was limited because of a lack of human and material resources.

Cited by 3 publications

References 16 publications

Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study

Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study

Axial spondyloarthritis guidelines – aiming for maximum impact

Maintien thérapeutique d’un second anti-TNF alpha dans les spondyloarthrites : étude multicentrique en situation réelle

Contact Info

Product

Resources

About